Rep. Maria Elvira Salazar Unloads Shares of Moderna, Inc. (NASDAQ:MRNA)

Key Points

• Rep. Maria Elvira Salazar sold $1,001–$15,000 of Moderna shares on September 24 from her UBS IRA account, alongside similarly sized sales of 10 other stocks including Microsoft, Meta, Salesforce and Citigroup.
• Moderna shares opened at $197, near their 52-week high of $212.22, despite continued losses. The company reported quarterly revenue of $145 million and an adjusted loss of $1.97 per share, while analysts expect a full-year loss of $6.09 per share.
• Analyst sentiment remains cautious: Moderna has a consensus “Hold” rating and a $78.17 target price, far below its recent trading level. The stock’s outlook is supported by Nasdaq-100 inclusion and cancer-vaccine developments, but risks include ongoing losses, high valuation and challenges scaling individualized therapies.

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. NASDAQ: MRNA. In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on September 24th. The trade occurred in the Representative's "UBS IRA ACCOUNT" account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Citigroup NYSE: C on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 9/24/2026.
• Sold $1,001 - $15,000 in shares of GE Aerospace NYSE: GE on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Honeywell International NASDAQ: HON on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 9/24/2026.
• Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Salesforce NYSE: CRM on 9/24/2026.
• Sold $1,001 - $15,000 in shares of RH NYSE: RH on 9/24/2026.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 9/24/2026.

Moderna Stock Performance

NASDAQ:MRNA opened at $197.00 on Friday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company has a market cap of $78.65 billion, a P/E ratio of -24.66 and a beta of 1.09. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $212.22. The firm's 50 day moving average is $136.67 and its two-hundred day moving average is $83.94.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.13) EPS. Analysts expect that Moderna, Inc. will post -6.09 EPS for the current year.

Insider Activity

In other Moderna news, CFO James M. Mock sold 34,836 shares of the firm's stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 118,882 shares of company stock worth $16,862,280 over the last ninety days. Corporate insiders own 10.80% of the company's stock.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Nasdaq-100 inclusion may create additional demand. Moderna’s entry into the index follows a reported 566% stock surge and could prompt buying by index-tracking funds. The move also increases the company’s visibility among institutional investors. Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
• Positive Sentiment: Progress in personalized cancer vaccines is strengthening Moderna’s post-COVID growth story. Moderna and Merck expanded a multi-year collaboration with Tempus to support potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being studied with Keytruda in melanoma and other cancers. A successful oncology franchise could diversify revenue beyond COVID vaccines. Tempus Announces Multi-Year Collaboration with Moderna and Merck
• Positive Sentiment: Manufacturing and technology developments are providing additional pipeline optimism. Moderna is applying lessons from its COVID-era production network to scale cancer therapies, while experimental AI research could eventually reduce cold-storage requirements for mRNA vaccines and improve distribution economics. Experimental approach uses AI to eliminate cold storage for mRNA vaccines
• Neutral Sentiment: Moderna’s broader pipeline of mRNA vaccines and oncology treatments is attracting investor interest, but many programs remain dependent on clinical, regulatory and commercial execution. Axsome Therapeutics vs. Moderna
• Negative Sentiment: Morgan Stanley maintained a cautious view. The firm rated Moderna “Equal Weight” or “Hold” and raised its price target only from $89 to $95, far below the recent trading level. That gap suggests the analyst believes expectations and valuation may be excessive. Moderna Gets a Hold from Morgan Stanley
• Negative Sentiment: Commentary warning that Moderna could be materially above fair value, combined with ongoing losses and the challenge of manufacturing individualized cancer treatments at scale, creates downside risk if clinical or commercial milestones disappoint. Moderna Could Be Above Fair Value

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRNA. Bradesco Corretora upgraded Moderna to an "outperform" rating in a report on Friday, August 28th. Piper Sandler reissued an "overweight" rating on shares of Moderna in a research report on Monday, August 3rd. Jefferies Financial Group reissued a "hold" rating on shares of Moderna in a research note on Wednesday, August 19th. Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a report on Friday, August 28th. They set a "hold" rating on the stock. Finally, CLSA raised shares of Moderna to an "outperform" rating in a research report on Friday, August 28th. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $78.17.

Institutional Investors Weigh In On Moderna

A number of large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in Moderna by 11.4% during the 3rd quarter. GAMMA Investing LLC now owns 16,136 shares of the company's stock valued at $3,107,000 after purchasing an additional 1,657 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Moderna by 14.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 17,622 shares of the company's stock worth $3,394,000 after buying an additional 2,193 shares in the last quarter. Everhart Financial Group Inc. purchased a new position in Moderna in the 3rd quarter valued at about $213,000. Avidian Wealth Enterprises LLC purchased a new position in Moderna in the 3rd quarter valued at about $352,000. Finally, Valeo Financial Advisors LLC grew its stake in shares of Moderna by 9.9% during the third quarter. Valeo Financial Advisors LLC now owns 8,147 shares of the company's stock valued at $1,569,000 after acquiring an additional 735 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida's 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida's 27th Congressional District. She won in the general election on November 5, 2024. Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company's work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.